Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutationsFatima Karzai, William L. Dahut, Ravi A. Madan et al.|Journal for ImmunoTherapy of Cancer|2018Cited by 312
Prostate Epithelial Pten/TP53 Loss Leads to Transformation of Multipotential Progenitors and Epithelial to Mesenchymal TransitionPhilip Martin, Kathleen Kelly|American Journal Of Pathology|2011Cited by 100
TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformationMichael D. Oberst, Kathleen Kelly|BMC Cancer|2008Cited by 50
High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancerKeith H. Jansson, Kathleen Kelly|Scientific Reports|2018Cited by 33